Abstract 872: High quality on-demand gene edited human primary T cells

Abstract EditCo unveils a breakthrough in T cell engineering aimed at benefiting cancer research: a rapid platform delivering premium-quality edited human CD4+ and CD8+ T cells with unprecedented efficiency. The platform achieves knock-out efficiency greater than 80% in less than 2 weeks, with edited cell pools maintaining viability above 70% before cryopreservation. These cells can be thawed and expanded at least 30-fold over 14 days independent of TCR stimulation, with no loss in editing efficiency. The platform's versatility has been demonstrated across multiple unique gene targets critical to cancer research and diverse donor populations, ensuring broad applicability. Notably, edited CD4+ T cells retain robust functionality after cryo-recovery, producing IL2, IFNγ, and TNFα upon stimulation. Similarly, edited CD8+ T cells maintain their endogenous antigen-specific cytotoxic activity, successfully express lentiviral CAR-T constructs, and demonstrate bi-specific engager-mediated cell killing. This comprehensive validation establishes EditCo's platform as a versatile, high-performance solution for T cell editing, maintaining cellular integrity and functionality while delivering consistent results across multiple genetic targets and donor populations. Citation Format: John Latimer, Daniel Orozco, Paolo Piazza, Alex Brown. High quality on-demand gene edited human primary T cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 872.